Philippe E Van Den Steen

List of Publications by Year
in descending order

104 papers	8,930 citations	71004 43 h-index	48101 92 g-index
104 all docs	104 docs citations	104 times ranked	12337 citing authors

#	Article	IF	Citations
1	Neutrophils in malaria: The good, the bad or the ugly?. Parasite Immunology, 2022, 44, e12912.	0.7	5
2	Taming the neutrophil: Balance between antiâ€parasite defence and pathogenesis. Parasite Immunology, 2022, 44, .	0.7	0
3	Hemozoin in Malarial Complications: More Questions Than Answers. Trends in Parasitology, 2021, 37, 226-239.	1.5	16
4	Etiology of lactic acidosis in malaria. PLoS Pathogens, 2021, 17, e1009122.	2.1	29
5	Skeleton binding protein-1-mediated parasite sequestration inhibits spontaneous resolution of malaria-associated acute respiratory distress syndrome. PLoS Pathogens, 2021, 17, e1010114.	2.1	7
6	von Willebrand factor increases in experimental cerebral malaria but is not essential for lateâ€stage pathogenesis in mice. Journal of Thrombosis and Haemostasis, 2020, 18, 2377-2390.	1.9	2
7	CCR2 Is Dispensable for Disease Resolution but Required for the Restoration of Leukocyte Homeostasis Upon Experimental Malaria-Associated Acute Respiratory Distress Syndrome. Frontiers in Immunology, 2020, 11, 628643.	2.2	10
8	Critical Roles of Endogenous Glucocorticoids for Disease Tolerance in Malaria. Trends in Parasitology, 2019, 35, 918-930.	1.5	8
9	Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic lymphocytic leukemia cells. Biochemical and Biophysical Research Communications, 2019, 520, 198-204.	1.0	8
10	Limitations of neutrophil depletion by anti-Ly6G antibodies in two heterogenic immunological models. Immunology Letters, 2019, 212, 30-36.	1.1	25
11	von Willebrand factor in experimental malariaâ€associated acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis, 2019, 17, 1372-1383.	1.9	8
12	MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest. Oncogene, 2019, 38, 4605-4619.	2.6	11
13	Release of endothelial activation markers in lungs of patients with malaria-associated acute respiratory distress syndrome. Malaria Journal, 2019, 18, 395.	0.8	6
14	Experimental malaria-associated acute respiratory distress syndrome is dependent on the parasite-host combination and coincides with normocyte invasion. Malaria Journal, 2018, 17, 102.	0.8	25
15	A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of chronic lymphocytic leukemia cells by altering migration regulatory pathways. Biochemical and Biophysical Research Communications, 2018, 495, 124-130.	1.0	7
16	Adrenal hormones mediate disease tolerance in malaria. Nature Communications, 2018, 9, 4525.	5.8	27
17	Differential induction of malaria liver pathology in mice infected with Plasmodium chabaudi AS or Plasmodium berghei NK65. Malaria Journal, 2018, 17, 18.	0.8	19
18	11Î²-hydroxysteroid dehydrogenase type 1 has no effect on survival during experimental malaria but affects parasitemia in a parasite strain-specific manner. Scientific Reports, 2017, 7, 13835.	1.6	5

#	Article	IF	Citations
19	Astemizole analogues with reduced hERG inhibition as potent antimalarial compounds. Bioorganic and Medicinal Chemistry, 2017, 25, 6332-6344.	1.4	17
20	Pathogenic CD8+ T Cells Cause Increased Levels of VEGF-A in Experimental Malaria-Associated Acute Respiratory Distress Syndrome, but Therapeutic VEGFR Inhibition Is Not Effective. Frontiers in Cellular and Infection Microbiology, 2017, 7, 416.	1.8	18
21	Plasmodium berghei NK65 in Combination with IFN-Î³ Induces Endothelial Glucocorticoid Resistance via Sustained Activation of p38 and JNK. Frontiers in Immunology, 2017, 8, 1199.	2.2	9
22	Endothelial Response to Glucocorticoids in Inflammatory Diseases. Frontiers in Immunology, 2016, 7, 592.	2.2	76
23	The immunological balance between host and parasite in malaria. FEMS Microbiology Reviews, 2016, 40, 208-257.	3.9	112
24	Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. Biochemical Journal, 2015, 465, 259-270.	1.7	39
25	Replication of Plasmodium in reticulocytes can occur without hemozoin formation, resulting in chloroquine resistance. Journal of Experimental Medicine, 2015, 212, 893-903.	4.2	62
26	CXCR3 ligands in disease and therapy. Cytokine and Growth Factor Reviews, 2015, 26, 311-327.	3.2	239
27	Altered Lipid Composition of Surfactant and Lung Tissue in Murine Experimental Malaria-Associated Acute Respiratory Distress Syndrome. PLoS ONE, 2015, 10, e0143195.	1.1	13
28	Contribution of the Ly49E Natural Killer Receptor in the Immune Response to Plasmodium berghei Infection and Control of Hepatic Parasite Development. PLoS ONE, 2014, 9, e87463.	1.1	4
29	Hemozoin Induces Hepatic Inflammation in Mice and Is Differentially Associated with Liver Pathology Depending on the Plasmodium Strain. PLoS ONE, 2014, 9, e113519.	1.1	30
30	Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen. Journal of Leukocyte Biology, 2014, 96, 185-199.	1.5	23
31	Inhibition of Neutrophil Collagenase/MMP-8 and Gelatinase B/MMP-9 and Protection against Endotoxin Shock. Journal of Immunology Research, 2014, 2014, 1-10.	0.9	6
32	Immunopathological effects of malaria pigment or hemozoin and other crystals. BioFactors, 2014, 40, 59-78.	2.6	17
33	Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen. Journal of Leukocyte Biology, 2014, , .	1.5	1
34	MalarImDB: an open-access literature-based malaria immunology database. Trends in Parasitology, 2014, 30, 309-316.	1.5	5
35	Chemically Synthesized Matrix Metalloproteinase and Angiogenesis-inhibiting Peptides as Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 483-494.	0.9	7
36	Hemozoin Induces Lung Inflammation and Correlates with Malaria-Associated Acute Respiratory Distress Syndrome. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 589-600.	1.4	76

#	Article	IF	Citations
37	Pathogenesis of malaria-associated acute respiratory distress syndrome. Trends in Parasitology, 2013, 29, 346-358.	1.5	79
38	Zymography methods for visualizing hydrolytic enzymes. Nature Methods, 2013, 10, 211-220.	9.0	271
39	Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Critical Reviews in Biochemistry and Molecular Biology, 2013, 48, 222-272.	2.3	622
40	Natural Haemozoin Induces Expression and Release of Human Monocyte Tissue Inhibitor of Metalloproteinase-1. PLoS ONE, 2013, 8, e71468.	1.1	15
41	Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes. Combinatorial Chemistry and High Throughput Screening, 2012, 15, 555-570.	0.6	18
42	Enzymatic processing by MMPâ€2 and MMPâ€9 of wildâ€type and mutated mouse Î²â€dystroglycan. IUBMB Life, 2012, 64, 988-994.	1.5	20
43	Meprins process matrix metalloproteinaseâ€9 (MMPâ€9)/gelatinase B and enhance the activation kinetics by MMPâ€3. FEBS Letters, 2012, 586, 4264-4269.	1.3	22
44	Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-Î± converting enzyme (TACE/ADAM-17). Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 533-540.	2.5	8
45	Improved methods for haemozoin quantification in tissues yield organ-and parasite-specific information in malaria-infected mice. Malaria Journal, 2012, 11, 166.	0.8	26
46	Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. , 2012, 133, 257-279.		98
47	Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease. Journal of Autoimmunity, 2011, 36, 239-252.	3.0	46
48	Natural haemozoin modulates matrix metalloproteinases and induces morphological changes in human microvascular endothelium. Cellular Microbiology, 2011, 13, 1275-1285.	1.1	42
49	Ajuga remota Benth.: From ethnopharmacology to phytomedical perspective in the treatment of malaria. Phytomedicine, 2011, 18, 1229-1237.	2.3	29
50	Insufficiently Defined Genetic Background Confounds Phenotypes in Transgenic Studies As Exemplified by Malaria Infection in Tlr9 Knockout Mice. PLoS ONE, 2011, 6, e27131.	1.1	16
51	Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain. World Journal of Biological Chemistry, 2011, 2, 14.	1.7	56
52	Matrix Metalloproteinase-9 Promotes Chronic Lymphocytic Leukemia B Cell Survival through Its Hemopexin Domain. Cancer Cell, 2010, 17, 160-172.	7.7	138
53	Enzymatic degradation of adhesiveâ€“dentin interfaces produced by mild selfâ€etch adhesives. European Journal of Oral Sciences, 2010, 118, 494-501.	0.7	89
54	Immunopathology and Dexamethasone Therapy in a New Model for Malaria-associated Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 957-968.	2.5	96

#	Article	IF	Citations
55	Immunopathology and dexamethasone therapy in a new model for malaria-associated acute respiratory distress syndrome. Malaria Journal, 2010, 9, .	0.8	0
56	Direct Visualization of Protease Action on Collagen Triple Helical Structure. PLoS ONE, 2010, 5, e11043.	1.1	70
57	Abstract LB-342: Matrix metalloproteinase-9 is a novel pathogenic factor in B-cell chronic lymphocytic leukemia. , 2010, , .		0
58	Neutrophil MMP-9 Proenzyme, Unencumbered by TIMP-1, Undergoes Efficient Activation in Vivo and Catalytically Induces Angiogenesis via a Basic Fibroblast Growth Factor (FGF-2)/FGFR-2 Pathway. Journal of Biological Chemistry, 2009, 284, 25854-25866.	1.6	119
59	Inhibition of Enzymatic Degradation of Adhesive-Dentin Interfaces. Journal of Dental Research, 2009, 88, 1101-1106.	2.5	206
60	â€œReverse degradomicsâ€• monitoring of proteolytic trimming by multiâ€CE and confocal detection of fluorescent substrates and reaction products. Electrophoresis, 2009, 30, 2366-2377.	1.3	13
61	The Collagen Binding Domain of Gelatinase A Modulates Degradation of Collagen IV by Gelatinase B. Journal of Molecular Biology, 2009, 386, 419-434.	2.0	44
62	CXCR3 determines strain susceptibility to murine cerebral malaria by mediating Tâ€„lymphocyte migration toward IFNâ€Î³â€‐induced chemokines. European Journal of Immunology, 2008, 38, 1082-1095.	1.6	97
63	Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis. Virology, 2008, 382, 20-27.	1.1	15
64	Adenylyl cyclase-associated protein-1/CAP1 as a biological target substrate of gelatinase B/MMP-9. Experimental Cell Research, 2008, 314, 2739-2749.	1.2	19
65	Virus entry inhibition by chlorite-oxidized oxyamylose versus induction of antiviral interferon by poly(I:C). Biochemical Pharmacology, 2008, 76, 831-840.	2.0	10
66	Î²-Hematin Interaction with the Hemopexin Domain of Gelatinase B/MMP-9 Provokes Autocatalytic Processing of the Propeptide, Thereby Priming Activation by MMP-3. Biochemistry, 2008, 47, 2689-2699.	1.2	54
67	Î±4Î²1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood, 2008, 112, 169-178.	0.6	140
68	The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases. Critical Reviews in Biochemistry and Molecular Biology, 2007, 42, 113-185.	2.3	325
69	Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins. Journal of Leukocyte Biology, 2007, 81, 870-892.	1.5	135
70	A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 178-186.	1.1	81
71	Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature Reviews Drug Discovery, 2007, 6, 480-498.	21.5	680
72	Insights into the Structure and Domain Flexibility of Full-Length Pro-Matrix Metalloproteinase-9/Gelatinase B. Structure, 2007, 15, 1227-1236.	1.6	113

#	Article	IF	Citations
73	Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. International Ophthalmology, 2007, 27, 11-22.	0.6	42
74	Cancer-Associated Glycoforms of Gelatinase B Exhibit a Decreased Level of Binding to Galectin-3â€. Biochemistry, 2006, 45, 15249-15258.	1.2	20
75	Remnant epitopes, autoimmunity and glycosylation. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 610-615.	1.1	38
76	Matrix metalloproteinases, tissue inhibitors of MMPs and TACE in experimental cerebral malaria. Laboratory Investigation, 2006, 86, 873-888.	1.7	64
77	Inhibition of Lethal Endotoxin Shock with an L-Pyridylalanine Containing Metalloproteinase Inhibitor Selected by High-Throughput Screening of a New Peptide Library. Combinatorial Chemistry and High Throughput Screening, 2006, 9, 599-611.	0.6	14
78	The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors. Journal of Biological Chemistry, 2006, 281, 18626-18637.	1.6	163
79	Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochemical Pharmacology, 2005, 70, 535-544.	2.0	49
80	Differential Glycosylation of Gelatinase B from Neutrophils and Breast Cancer Cells. Advances in Experimental Medicine and Biology, 2005, 564, 103-112.	0.8	1
81	Gelatinase B/matrix metalloproteinaseâ€9 provokes cataract by cleaving lens Î²B1 crystallin. FASEB Journal, 2005, 19, 29-35.	0.2	30
82	Simulation of Evolution-Selected Propeptide by High-Throughput Selection of a Peptidomimetic Inhibitor on a Capillary DNA Sequencer Platform. Analytical Chemistry, 2005, 77, 2116-2124.	3.2	21
83	Inhibitors of gelatinase B/matrix metalloproteinase-9 activity. Biochemical Pharmacology, 2004, 67, 1001-1009.	2.0	38
84	Generation of Glycosylated Remnant Epitopes from Human Collagen Type II by Gelatinase B. Biochemistry, 2004, 43, 10809-10816.	1.2	50
85	A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys Î±B-crystallin and generates a promiscuous T cell epitope. Journal of Neuroimmunology, 2003, 141, 47-57.	1.1	46
86	Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. FEBS Journal, 2003, 270, 3739-3749.	0.2	253
87	Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochemical and Biophysical Research Communications, 2003, 310, 889-896.	1.0	97
88	Neutralizing antibodies in gene-defective hosts. Trends in Immunology, 2003, 24, 94-100.	2.9	18
89	Gelatinase B/matrix metalloproteinaseâ€9 cleaves interferonâ€Î² and is a target for immunotherapy. Brain, 2003, 126, 1371-1381.	3.7	93
90	Remnant Epitopes Generate Autoimmunity: From Rheumatoid Arthritis and Multiple Sclerosis to Diabetes. Advances in Experimental Medicine and Biology, 2003, 535, 69-77.	0.8	33

#	Article	IF	Citations
91	Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin. FASEB Journal, 2003, 17, 1-13.	0.2	61
92	Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, postâ€translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB Journal, 2002, 16, 379-389.	0.2	167
93	Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9). Critical Reviews in Biochemistry and Molecular Biology, 2002, 37, 375-536.	2.3	805
94	Neutrophil Gelatinase B and Chemokines in Leukocytosis and Stem Cell Mobilization. Leukemia and Lymphoma, 2002, 43, 233-241.	0.6	49
95	Matrix remodelling enzymes, the protease cascade and glycosylation. Biochimica Et Biophysica Acta - General Subjects, 2001, 1528, 61-73.	1.1	84
96	Gelatinase B: a tuner and amplifier of immune functions. Trends in Immunology, 2001, 22, 571-579.	2.9	363
97	Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-Î± and leaves RANTES and MCP-2 intact. Blood, 2000, 96, 2673-2681.	0.6	615
98	Structural Characterization of the Catalytic Active Site in the Latent and Active Natural Gelatinase B from Human Neutrophils. Journal of Biological Chemistry, 2000, 275, 34335-34343.	1.6	26
99	O-Glycan Analysis of Natural Human Neutrophil Gelatinase B Using a Combination of Normal Phase-HPLC and Online Tandem Mass Spectrometry:Â Implications for the Domain Organization of the Enzymeâ€. Biochemistry, 2000, 39, 15695-15704.	1.2	87
100	Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-Î± and leaves RANTES and MCP-2 intact. Blood, 2000, 96, 2673-2681.	0.6	23
101	Glycosylation of Natural Human Neutrophil Gelatinase B and Neutrophil Gelatinase B-Associated Lipocalin. Biochemistry, 1999, 38, 13937-13950.	1.2	108
102	Oligosaccharides of recombinant mouse gelatinase B variants. Biochimica Et Biophysica Acta - General Subjects, 1998, 1425, 587-598.	1.1	24
103	Concepts and Principles of O-Linked Glycosylation. Critical Reviews in Biochemistry and Molecular Biology, 1998, 33, 151-208.	2.3	633
104	Cytokine and Protease Glycosylation as a Regulatory Mechanism in Inflammation and Autoimmunity. Advances in Experimental Medicine and Biology, 1998, 435, 133-143.	0.8	31